E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
short bowel syndrome |
sindrome dell'intestino corto |
|
E.1.1.1 | Medical condition in easily understood language |
short gut |
intestino corto |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10049416 |
E.1.2 | Term | Short-bowel syndrome |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess long-term safety and tolerability of apraglutide in subjects with SBS-IF |
Valutare la sicurezza e la tollerabilità a lungo termine di apraglutide in soggetti con SBS-IF |
|
E.2.2 | Secondary objectives of the trial |
To evaluate markers indicative of clinical effects of apraglutide |
Valutare i marcatori indicativi di effetti clinici di apraglutide |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females with a diagnosis of SBS-IF secondary to surgical resection of the small intestine, with CIC or stoma, who have completed parent trials TA799-007 or TA799-013 and: a. Did not meet any stopping criteria. b. Received a minimum of 70% of the planned doses in the trial (unless an AE precluded the subject from meeting this percentage; in this case, the Investigator will decide if the subject will benefit from enrolling in the trial). c. Complete the last two scheduled visits of the parent trial. Subjects who were forced to withdraw from TA799-007 for logistical reasons not related to the efficacy or safety of apraglutide (e.g., hospitalization for a car accident, COVID-19 pandemic, or emergency surgery) which resulted in several consecutive missed doses may be eligible to participate in this trial upon approval by the Medical Monitor. 2. Able to give informed consent and agree to follow the details of participation as outlined in this protocol. 3. Women of childbearing potential must agree to use a highly effective method of contraception during the trial and for 4 weeks after the end of trial (EOT) visit. 4. Male subjects with a female partner of childbearing potential must commit to practice methods of contraception and abstain from sperm donation during the trial and for 2 weeks after the EOT Visit. |
1. Soggetti di ambo i sessi con diagnosi di SBS-IF secondaria a resezione chirurgica dell’intestino tenue, con CIC o stomia, che hanno completato lo studio originario TA799-007 o TA799-013 e: a. Non hanno soddisfatto i criteri di interruzione. b. Hanno ricevuto almeno il 70% delle dosi previste nello studio (eccetto laddove un AE abbia impedito al soggetto di soddisfare questa percentuale; in tal caso, lo sperimentatore deciderà se il soggetto trarrà beneficio dall’arruolamento nello studio). c. Si sono sottoposti alle ultime due visite programmate dello studio originario. I soggetti che sono stati costretti a ritirarsi dallo studio TA799-007 per motivi logistici non correlati all’efficacia o alla sicurezza di apraglutide (ad es. ricovero in ospedale per un incidente d’auto, a causa della pandemia da COVID-19 o per un intervento chirurgico d’emergenza) e che di conseguenza hanno saltato diverse dosi consecutive potranno essere ritenuti idonei alla partecipazione allo studio su autorizzazione del Medical Monitor. 2. Soggetti in grado di rilasciare il consenso informato e che acconsentono a rispettare le specifiche della partecipazione riportate nel presente protocollo. 3. Le donne in età fertile dovranno acconsentire a usare un metodo contraccettivo altamente efficace durante la sperimentazione e per 4 settimane dopo la visita di fine studio (EOT). 4. I soggetti di sesso maschile con una partner in età fertile dovranno impegnarsi a usare metodi contraccettivi e ad astenersi dalla donazione del seme durante la sperimentazione e per 2 settimane dopo la visita EOT. |
|
E.4 | Principal exclusion criteria |
1. Subject not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements. 2. Any other reason judged not eligible by the Investigator. |
1. Soggetti che non sono in grado di comprendere o non vogliono rispettare il programma delle visite dello studio e altri requisiti del protocollo. 2. Qualsiasi altro motivo per cui i soggetti siano ritenuti non idonei dallo sperimentatore. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Adverse events (AE; system organ class, frequency and severity) - Occurrence of clinically relevant AEs of special interest (AESIs): o Injection site reactions o Gastrointestinal (GI) obstructions o Gallbladder, biliary and pancreatic disease o Fluid overload o Colorectal polyps o Malignancies - Clinical chemistry, hematology, hemostasis and urinalysis - Occurrence of clinically relevant changes in vital signs (systolic and diastolic blood pressure, heart rate) - Occurrence of clinically relevant changes in electrocardiogram (ECG; intervals and rhythm) |
- Eventi avversi (AE; classificazione per sistemi e organi, frequenza e severità) - Comparsa di AE di interesse particolare (AESI) clinicamente rilevanti: o Reazioni nella sede di iniezione o Ostruzioni gastrointestinali (GI) o Disturbi a carico della colecisti, biliari e pancreatici o Sovraccarico di liquidi o Polipi del colon-retto o Neoplasie maligne - Esami biochimici, esami ematologici, esami per la valutazione dell’emostasi e analisi delle urine - Comparsa di variazioni clinicamente rilevanti dei parametri vitali (pressione arteriosa sistolica e diastolica, frequenza cardiaca) - Comparsa di variazioni clinicamente rilevanti nell’elettrocardiogramma (ECG; intervalli e ritmo) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in PS volume at Week 104 - Change from baseline in PS frequency at Week 104 - Change from baseline in PS composition at Week 104 - Change from baseline in PS infusion time at Week 104 - Percentage of subjects reaching enteral autonomy by Week 104 - Change from baseline in body weight at Week 104 - Change from baseline on QoL measures at Week 104 |
- Variazione rispetto al basale del volume di PS alla Settimana 104 - Variazione rispetto al basale della frequenza del PS alla Settimana 104 - Variazione rispetto al basale della composizione del PS alla Settimana 104 - Variazione rispetto al basale del tempo di infusione del PS alla Settimana 104 - Percentuale di soggetti che raggiungono l’autonomia enterale entro la Settimana 104 - Variazione rispetto al basale del peso corporeo alla Settimana 104 - Variazione rispetto al basale dei punteggi sulle scale QoL alla Settimana 104 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
China |
Israel |
Japan |
Korea, Republic of |
Taiwan |
United States |
Belgium |
Denmark |
France |
Germany |
Italy |
Norway |
Poland |
Spain |
Sweden |
United Kingdom |
Czechia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |